Information Provided By:
Fly News Breaks for February 17, 2020
TEVA
Feb 17, 2020 | 12:56 EDT
UBS analyst Kevin Caliendo raised his price target for Teva to $14 from $8, while keeping a Neutral rating on the shares as he awaits clarity on litigation costs.